Literature DB >> 27296559

Incidence, Causes, and Impact of In-Hospital Infections After Transcatheter Aortic Valve Implantation.

Gabriela Tirado-Conte1, Afonso B Freitas-Ferraz1, Luis Nombela-Franco2, Pilar Jimenez-Quevedo1, Corina Biagioni1, Ana Cuadrado1, Ivan Nuñez-Gil1, Pablo Salinas1, Nieves Gonzalo1, Carlos Ferrera1, David Vivas1, Javier Higueras1, Ana Viana-Tejedor1, Maria Jose Perez-Vizcayno1, Isidre Vilacosta1, Javier Escaned1, Antonio Fernandez-Ortiz1, Carlos Macaya1.   

Abstract

In-hospital infections (IHI) are one of the most common and serious problems after invasive procedures. Transcatheter aortic valve implantation (TAVI) is an increasingly used alternative to surgery in patients with severe symptomatic aortic stenosis. The aim of this study was to determine the incidence, origin, risk factors, and clinical outcomes of IHI after TAVI. A total of 303 consecutive patients with severe aortic stenosis who underwent transfemoral TAVI were included and followed during a median time of 21 months. We examined the occurrence, types, origin, and timing of infections during hospital stay as well as short- and long-term clinical outcomes according to the occurrence of IHI. A total of 51 patients (17%; 62 infectious episodes) experienced IHI after TAVI. Respiratory and urinary tract infections were the most frequent type of infections (44% and 34%, respectively), followed by surgical site infection (8%) and bloodstream infection (5%). Positive cultures were obtained in 74% of the samples, of which 65% were gram-negative bacilli. Modifiable factors such as bleeding (p = 0.005) and length of coronary care unit stay (p <0.001) were independently associated with an increased infection risk. Patients with IHI had a longer hospital stay (14 vs 6 days, p <0.001), an increased mortality (hazard ratio 2.48, 95% CI 1.45 to 4.23) and readmission rate (hazard ratio 2.0, 95% CI 1.27 to 3.14) during the follow-up. In conclusion, IHI is a frequent complication after TAVI with a significant impact on short- and long-term clinical outcomes. The most important risk factors associated with the development of this complication were modifiable periprocedural aspects. These results underline the importance to implement specific preventive strategies to reduce in-hospital-acquired infections after TAVI.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27296559     DOI: 10.1016/j.amjcard.2016.05.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement.

Authors:  Sahil Khera; Dhaval Kolte; Tanush Gupta; Andrew Goldsweig; Poonam Velagapudi; Ankur Kalra; Gilbert H L Tang; Wilbert S Aronow; Gregg C Fonarow; Deepak L Bhatt; Herbert D Aronow; Neal S Kleiman; Michael Reardon; Paul C Gordon; Barry Sharaf; J Dawn Abbott
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

2.  Infections after transcatheter versus surgical aortic valve replacement: mid-term results of 200 consecutive patients.

Authors:  Sharaf-Eldin Shehada; Daniel Wendt; Davina Peters; Fanar Mourad; Philipp Marx; Matthias Thielmann; Philipp Kahlert; Alexander Lind; Rolf-Alexander Janosi; Tienush Rassaf; Peter-Michael Rath; Martin Thoenes; Heinz Jakob; Mohamed El Gabry
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Use of Pre- and Intensified Postprocedural Physiotherapy in Patients with Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Study (the 4P-TAVR Study).

Authors:  M Weber; U Klein; A Weigert; W Schiller; V Bayley-Ezziddin; D C Wirtz; A Welz; N Werner; E Grube; G Nickenig; J-M Sinning; A Ghanem
Journal:  J Interv Cardiol       Date:  2021-01-16       Impact factor: 2.279

Review 4.  Risk Factors for Hospital Readmission Post-Transcatheter Aortic Valve Implantation in the Contemporary Era: A Systematic Review.

Authors:  Raumil V Patel; Mithunan Ravindran; Ragavie Manoragavan; Abi Sriharan; Harindra C Wijeysundera
Journal:  CJC Open       Date:  2022-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.